This is an aggregated industry headline. Read the full story at Drug Channels →
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
By Adam J. Fein, Ph.D.The 340B Drug Pricing Program continues to redefine the meaning of "skyrocketing." For 2025, discounted purchases under the 340B program reached an astounding $100 billion-23% higher than in 2024.The gross-to-net difference between list prices and discounted 340B purchases-a pr
By Drug Channels
· Jul 15, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Merck & Co.'s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent fo…
The WeekFierceBiotech ↗
Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inh…
The WeekBriefing
Biogen reported mid-stage trial data showing its Alzheimer’s drug slowed cognitive decline at rates similar to…